A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of RO7303509 in Participants With Systemic Sclerosis

NCT05462522 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

56

Enrollment

INDUSTRY

Sponsor class

Conditions

Systemic Sclerosis

Interventions

DRUG: RO7303509
DRUG: Placebo

Sponsor

Genentech, Inc.